Alexion Pharmaceuticals Inc ALXN:NASDAQ

Last Price$114.85NASDAQ Closing Price as of 4:00PM ET 10/28/20

Today's Change-5.15(4.29%)
Bid (Size)$112.60 (1)
Ask (Size)$115.00 (9)
Day Low / High$114.83 - 118.78
Volume1.8 M
  • Latest Stories
  • Commentary and Analysis
--Analyst Actions: UBS Starts Alexion Pharmaceuticals at Neutral With $133 Price Target
8:32AM ET 10/28/2020 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

Correction: Earnings Estimate Changes and Stock Price Data
5:59PM ET 10/18/2020 MT Newswires

On October 16-18, an outside data vendor for MT Newswires published incorrect earnings estimate changes and last stock price information for several...

Alexion Pharmaceuticals' Q3, 2020 and 2021 Earnings Estimates Scaled Up
3:55AM ET 10/17/2020 MT Newswires

Alexion Pharmaceuticals Inc's (NASDAQ:ALXN, Recent Price: 164.45) earnings targets for Q3 ending September 30, 2020, and the forecasts for 2020 and 2021...

Analyst Actions: Morgan Stanley Adjusts Price Target on Alexion Pharmaceuticals to $121 From $120, Keeps Equal-Weight Rating
9:55AM ET 10/13/2020 MT Newswires

Alexion Pharmaceuticals (ALXN) has an average rating of outperform and price targets ranging from $117 to $175, according to analysts polled by Capital IQ....

Alexion Pharmaceuticals Wins FDA Approval For New Formulation of Blood Disorder Drug Ultomiris
9:32AM ET 10/12/2020 MT Newswires

Alexion Pharmaceuticals (ALXN) said Monday the US Food and Drug Administration has approved the 100 mg/mL new formulation of Ultomiris for the treatment of...

Alexion Pharmaceuticals Phase 3 Study Treatment for Abnormal Blood Clots in Kidneys Delivers 'Improved' Outcome
3:24PM ET 10/09/2020 MT Newswires

Alexion Pharmaceuticals (ALXN) said Friday new data from phase 3 trials evaluating the efficacy and safety of ultomiris to treat pediatric patients with...

Research Alert: CFRA Keeps Strong Buy Opinion On Shares Of Alexion Pharmaceuticals
8:35AM ET 10/08/2020 MT Newswires

CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as...

Alexion Pharmaceuticals' Q3, 2020, 2021 Full Year Earnings Estimates Increased
11:20PM ET 10/07/2020 MT Newswires

Consensus estimates for Q3 ending September 30, 2020, and the full year forecasts for 2020 and 2021 for the years ending on December 31 for Alexion...

Analyst Actions: RBC Capital Adjusts Price Target on Alexion Pharmaceuticals to $139 From $136, Maintains Outperform Rating
7:22AM ET 10/07/2020 MT Newswires

Alexion Pharmaceuticals (ALXN) has an average rating of outperform and price targets ranging from $117 to $175, according to analysts polled by Capital IQ....

Sector Update: Health Care Firms Climb Premarket Tuesday
9:17AM ET 10/06/2020 MT Newswires

Health care firms were climbing premarket Tuesday. The Health Care SPDR (XLV) was gaining 0.18% in value and the iShares NASDAQ Biotechnology Index (IBB)...